WallStSmart

Basel Medical Group Ltd Ordinary Shares (BMGL)vsFresenius Medical Care Corporation (FMS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 131266% more annual revenue ($19.36B vs $14.74M). FMS leads profitability with a 4.9% profit margin vs -68.2%. FMS earns a higher WallStSmart Score of 50/100 (C-).

BMGL

Hold

38

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: -1.69

FMS

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 5.0Value: 8.7Quality: 6.0
Piotroski: 6/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BMGL.

FMSUndervalued (+68.5%)

Margin of Safety

+68.5%

Fair Value

$76.46

Current Price

$25.70

$50.76 discount

UndervaluedFair: $76.46Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BMGL2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
67.1%10/10

Revenue surging 67.1% year-over-year

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

FMS3 strengths · Avg: 8.7/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

PEG RatioValuation
0.888/10

Growing faster than its price suggests

P/E RatioValuation
13.4x8/10

Attractively priced relative to earnings

Areas to Watch

BMGL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.80M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.573/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

FMS4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.1%3/10

ROE of 7.1% — below average capital efficiency

Profit MarginProfitability
4.9%3/10

4.9% margin — thin

Revenue GrowthGrowth
-5.5%2/10

Revenue declined 5.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : BMGL

The strongest argument for BMGL centers on Revenue Growth, Price/Book. Revenue growth of 67.1% demonstrates continued momentum.

Bull Case : FMS

The strongest argument for FMS centers on Price/Book, PEG Ratio, P/E Ratio. PEG of 0.88 suggests the stock is reasonably priced for its growth.

Bear Case : BMGL

The primary concerns for BMGL are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.57 is elevated, increasing financial risk.

Bear Case : FMS

The primary concerns for FMS are Altman Z-Score, Return on Equity, Profit Margin. Thin 4.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

BMGL profiles as a hypergrowth stock while FMS is a value play — different risk/reward profiles.

BMGL is growing revenue faster at 67.1% — sustainability is the question.

FMS generates stronger free cash flow (37M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FMS scores higher overall (50/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Basel Medical Group Ltd Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Basel Medical Group Ltd provides healthcare services. The company is headquartered in Singapore.

Visit Website →

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Want to dig deeper into these stocks?